C6P / Jiangsu Hengrui Pharma - LARVOL DELTA

C6P, a claudin 6 (CLDN6) directed ADC containing pyrolobenzodiazepine (PBD) for the treatment of advanced solid tumors (AACR 2025) - "The intact ADC/total antibody AUC ratio was above 95%, and the payload was undetectable in the plasma of cynomolgus monkeys after injection with C6P. Overall, the highly specific CLDN6-targeting antibody, the optimized PBD payload, site-specific conjugation and well-controlled DAR value collectively contributed to the potent anti-tumor efficacy, and good safety profile of C6P, supporting its future clinical research."

Metastases • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • CLDN6